Introduction
High-dose therapy and autologous stem cell transplantation has been an important part of myeloma therapy ever since the initial randomized trials demonstrated a survival benefit for the procedure compared to conventional chemotherapy. [1] [2] [3] The standard of care, at least for average risk patients, remains initial induction therapy for their myeloma for 3-6 months followed by peripheral blood stem cell (PBSC) collection and immediate or delayed stem cell transplantation. 4, 5 Randomized trials have shown no disadvantage with opting for a delayed transplantation except for reduced time without therapy with the delayed approach. 6 While the timing of stem cell collection with respect to the diagnosis vary considerably from center to center, the types of induction therapy employed has been fairly consistent in its exclusion of alkylating agents, especially melphalan.
Previous studies have suggested an adverse impact of melphalan exposure on the stem cell pool and its potential to impede stem cell collection. 7 These effects of melphalan have been related to the cumulative dose as well as the specific dosing schedule employed; however, no prospective trial has systematically examined the factors influencing the ability to collect stem cell after exposure to melphalan. [8] [9] [10] [11] Recent advances in the field, including the potential impact of tandem stem cell transplant and introduction of very effective agents such as bortezomib and lenalidomide have changed the landscape of treatment of myeloma. [12] [13] [14] [15] [16] [17] [18] [19] The impacts of these changes on the role of stem cell transplant are many. These include the demonstration of a survival benefit with tandem stem cell transplantation, especially for those patients failing to achieve a VGPR with the first transplant, which has resulted in larger stem cell requirements. This coupled with the demonstrated role of salvage stem cell transplant at relapse, especially for patients deriving a long progression free survival from the initial transplant has resulted in many institutions attempting to collect stem cells for up to three transplants. 20, 21 This is balanced by a paradigm shift in the approach to initial therapy given the high response rates associated with initial treatment regimens that incorporate novel agents such as lenalidomide and bortezomib. 15, 22 Given the high rates of VGPR seen with these agents, especially with continued therapy, there is a growing trend to delay transplant to the time of initial relapse and many patients are starting to opt for collecting stem cells and delaying application of high-dose therapy (Lacy M et al. Blood 2006; 108: 798, abstract).
The induction regimens previously in vogue such as high-dose dexamethasone and vincristine-adriamycin-dexamethasone (VAD) have not been shown to have any adverse effects on the ability to collect adequate stem cells. There remains some controversy regarding the effect of thalidomide on stem cell collection and engraftment with studies showing discordant results. [23] [24] [25] [26] Unlike thalidomide and dexamethasone, marrow suppression is a prominent adverse effect of lenalidomide (Rajkumar SV et al. Blood 2006 ; 108: 799, abstract). The regimen of lenalidomide and low-dose dexamethasone have been associated with one of the lowest initial mortality rate following diagnosis of myeloma and this coupled with the ease of an oral regimen has resulted in this regimen's widespread use as induction therapy. However, given the myelotoxicity seen with this regimen, there have been concerns regarding its potential impact on stem cell collection, both in terms of the numbers of CD34 cells mobilized as well as the quality of stem cells. 15 In this study, we retrospectively examined the results of stem cell collection and engraftment after stem cell transplantation in a cohort of patients receiving initial therapy with lenalidomide and dexamethasone at our institution, comparing these results to those of patients receiving single agent dexamethasone, VAD or thalidomide dexamethasone as initial therapy.
Patients and methods

Patients
Between 1 January 2002 and 31 December 2006, stem cell mobilization was attempted on 562 patients with multiple myeloma at Mayo Clinic, Rochester. Among these, 382 patients who had stem cells collected within 12 months of their diagnosis, who had received either single agent dexamethasone, VAD, thalidomide-dexamethasone or lenalidomide-dexamethasone, and who had received only one induction regimen before the attempt at stem-cell mobilization were identified (Figure 1 ). Among these 382 patients, there were six patients who were enrolled in the multicenter study of AMD3100 (a CXCR4 inhibitor), which were ongoing during this time frame and were excluded from the analyses. Of these 376 patients, 134 patients (35.6%) was mobilized with cyclophosphamide pulsing followed by granulocyte-colony stimulating factor (G-CSF, filgrastim) injections and 242 patients (64.3%) had stem cells mobilized with G-CSF alone. The decision to use cyclophosphamide was usually based on the presence of circulating clonal plasma cells at the time of pretransplant evaluation as measured by slide-based immunofluorescence method described previously. Patients with circulating plasma cells, indicating active disease for most part, received 1.5 g/m 2 of cyclophosphamide given on 2 consecutive days followed by initiation of growth factors and its continuation until stem cell collection was completed. GCSF was started at 10 mcg/kg/day with dose increased up to 16 mcg/kg twice daily in the absence of adequate peripheral blood CD34 counts or poor CD34 counts in the collection. Apheresis was initiated once peripheral blood CD34 counts are over 10/ml and continued until goals for individual patients were met. We generally have targeted 3-4 million CD34 þ cells/kg for each transplant, and patients had collections performed for 1-3 transplants depending on clinical scenario and patient preference. All the data were extracted from patient medical records and from the prospectively maintained transplant data base. The study was approved by the Mayo Foundation Institutional Review Board and all patients consented to have their medical records reviewed according to institutional review board practices and Health Insurance Portability and Accountability Act (HIPAA) guidelines.
Several parameters were used to compare efficiency of stem cell collection, namely the total CD34 yield, the number of collections performed, the average CD34 cell collection per day, the total CD34 yield on day 1, first 2 days and the first 3 days of collection. We decided to use these multiple endpoints since each may be influenced by different factors in individual patients. The total CD34 collection and the number of days of collection are dependent on the final target, which in turn often is based on patient's preference, possibility of tandem transplant as well as patient age and performance status. When daily collection numbers start falling, the dose of the growth factor is often increased. However, such changes are unlikely to affect the first 3 days of collection and hence we also looked at the CD34 yield on the first day of collection, the first 2 days and the first 3 days. Fisher's exact test was used to test differences in nominal variables between groups. Differences in continuous variable between groups were compared using Mann-Whitney or Kruskal-Wallis tests. All analyses were performed using Statview (SAS, Cary, NC, USA).
Results
Three hundred and seventy-six patients were included in the final analysis of stem cell collection outcome. The median age of the entire group was 59 years at the time of stem cell collection (range, 33-75) and 224 were men (59.6%). The median time for collection from diagnosis was 5.5 months (range; 2.7-11.9). Single agent dexamethasone (Dex) was used for initial treatment in 147 patients (39.1%), thalidomidedexamethasone (Thal-Dex) in 135 (35.9%), lenalidomidedexamethasone (Len-Dex) in 48 (12.8%) and VAD in 46 (12.2%). The patients receiving VAD were slightly younger compared to the rest and the median age (range) at collection for the VAD, Dex, Thal-Dex and Len-Dex groups being 55.7 (33-72), 60.4 (38-73), 57.3 (37-75) and 60.6 (33-75) years respectively (P ¼ 0.046). The corresponding proportion of patients over age 65 with each induction regimen was 19.6, 28.6, 18.5 and 37.5%, respectively. Among the patients going for stem cell collection, 332 (88.3%) had proceeded to highdose therapy and stem cell transplant at the time of analysis. There was no difference in the age or sex distribution among patients going for stem cell transplant compared to those who only had cells harvested. We first examined the effect of cyclophosphamide pulsing on the stem cell yield. There were significant differences in the proportion of patients receiving cyclophosphamide pulsing for stem cell mobilization with each induction regimen, with very few patients in the Len-Dex arm receiving cyclophosphamide compared to those receiving Dex induction (Po0.001) ( Table 1) . This is a reflection of the better disease control seen with the lenalidomide compared to the other regimens. Among the entire group, 134 patients (35.6%) mobilized with cyclophosphamide had a significantly higher total CD34 yield, higher average daily CD34 and higher CD34 yields on first day, first 2 days and first 3 days and fewer collections ( Table 2) . Given these findings, we analyzed the patients receiving growth factor alone for mobilization separately.
The median age of the 242 patients receiving growth factor alone for mobilization was 59.3 years (range; 33-75) and 141 patients (58.2%) were men. Thal-Dex was used for initial treatment in 99 patients (40.9%), Dex in 78 (32.2%), Len-Dex in 43 (17.8%) and VAD in 22 (9.1%) respectively. Patients Figure 1 Schema describing patient selection for the current study. VAD, vincristine-adriamycin-dexamethasone; Thal-Dex, thalidomide and dexamethasone; Len-Dex, lenalidomide and dexamethasone; AMD, multicenter randomized AMD3100 stem cell mobilization clinical trial; ASCT, autologous peripheral blood stem cell transplant.
Lenalidomide and stem cell mobilization in myeloma S Kumar et al receiving Len-Dex for induction had a significantly lower total CD34 yield, lower average daily CD34 and lower CD34 collection on first day, first 2 days and first 3 days and a greater number of collections ( Figure 2 , Table 3 ). Three patients were not able to proceed to stem cell collection having failed to achieve the threshold peripheral blood CD34 counts (10/ml) and all three of these patients had received Len-Dex for induction. Two additional patients failed to collect at least 2.5 million CD34 cells/kg, the minimum target required for a transplant, one of whom had received single agent Dex and one had received VAD. We looked at different variables that potentially predicted inability to collect stem cells among the Len-Dextreated patients. There was a trend towards decreased day 1 collection yield as well as average daily collection with increasing duration of Len-Dex therapy before stem cell harvest (r ¼ 0.159, P ¼ 0.02). All three patients who completely failed to mobilize, had been treated with Len-Dex for more than 6 months as induction therapy; they had received therapy for 7, 9 and 11 months before attempting stem cell collection and all three were over 67 years of age ( Figure 3 ). There was also a trend towards decreasing average CD34 collection as well as the day 1 collection with increasing age that was similar across all different induction regimens (r ¼ 0.219, P ¼ 0.002, Figure 4) . Among the 134 patients who were mobilized with cyclophosphamide and growth factors, there were only five patients, who had Len-Dex for induction therapy. There was a trend towards decreased average daily CD34 collection and a significantly lower day 1 collection in patients receiving Len-Dex. The parameters were similar among the other three induction regimens being studied ( Figure 5 , Table 4 ). Three patients failed to reach the threshold peripheral blood CD34 counts, one each with Dex, Thal-Dex and VAD inductions. Two additional patients failed to reach the minimum target of 2.5 million CD34/kg, one of who had Dex induction and one who had Thal-Dex induction.
We then analyzed the engraftment kinetics in patients going to stem cell transplant. Among the 376 patients undergoing stem cell collection, 332 patients had undergone a peripheral blood stem cell transplant (PBSCT) at the time of analysis. The median age of the patients at transplant was 58.8 years (33-75.4) and included 194 men (58.4%) and the median age at collection was similar for those proceeding to transplant versus continuing with induction therapy. For technical reasons, the methodology for freezing CD34 cells underwent a revision in April 2003 and only the 254 transplants performed using stem cells collected after that date were included for the analysis of engraftment. These included 105 patients (41.3%) treated initially with Thal-Dex, 97 (38.2%) treated with Dex, 31 (12.2%) with Len-Dex and 21 (18.3%) with VAD. The median time to neutrophil engraftment (defined as ANC4500/ml for 2 consecutive days) and platelet engraftment (platelets450 000/ml for 2 consecutive days without any need for transfusion) were similar between the groups ( Figure 6 ). There was no difference in the proportion of patients from each group who engrafted neutrophils by day 21 and platelets by day 30. All patients previously treated with Len-Dex had engrafted their neutrophils by day 21 and all except one had engrafted platelets by day 30. The median duration of hospitalization was similar among the groups.
Discussion
High-dose therapy and stem cell transplantation remains an important component of the therapeutic approach to the patient with newly diagnosed myeloma, who can undergo the procedure. [1] [2] [3] 6, 12, 27, 28 While patients responding to and tolerating the initial therapy may decide to delay transplant, it is important to keep this option open for future consideration. Given the potential impact of various chemotherapeutic agents utilized for treating myeloma on the ability to collect adequate numbers of stem cells, the conventional approach has been to collect stem cells after a brief period of initial therapy (usually 4-6 months) and then either proceeding to stem cell transplant or continuing the same therapy with the option of transplant later on. Initial studies have already confirmed the lack of any survival advantage of an early transplant and it is more than likely that this option will be more widely applied with the availability of new therapies that have since become available. 6 The impact of initial therapy on stem cell harvest has been most striking with the use of alkylating agents, especially melphalan, which has been a part of myeloma therapy for over four decades. [7] [8] [9] Studies have shown that use of melphalan impairs the stem cell reserve and adversely impacts the stem cell mobilization, an effect that appears to depend on the duration of Table 1 Comparison of the initial therapy of myeloma and the stem cell mobilization strategy Abbreviations: CTX, cyclophosphamide; Dex, dexamethasone; G-CSF, granulocyte-colony stimulating factor; Len-Dex, lenalidomide-dexamethasone; Thal-Dex, thalidomide-dexamethasone; VAD, vincristine-adriamycin-dexamethasone. Abbreviations: CTX, cyclophosphamide; G-CSF, granulocyte-colony stimulating factor.
Lenalidomide and stem cell mobilization in myeloma S Kumar et al melphalan exposure as well the doses administered. 10,11 VAD or single-agent dexamethasone has been the most widely used induction regimen before the advent of new drugs such as thalidomide, ImiDs and bortezomib.
During the past few years, based on the results from randomized phase III trials demonstrating improved response rates with thalidomide and dexamethasone, this combination gradually became a common initial therapy for myeloma. More recent trials have demonstrated even better results with the lenalidomide, an IMiD, when used in combination with dexamethasone. The activity of these drugs in myeloma results from multiple mechanisms including effect on bone marrow angiogenesis, immunomodulatory activity, as well as direct cytotoxicity on myeloma cells. These drugs have been shown to modify the expression of different adhesion molecules and other surface proteins on myeloma cells. This combined with its potential anti-angiogenic activity raised the concern whether it may adversely impact the ability to collect stem cells. Several retrospective studies as well as the data from prospective clinical trials where thalidomide had been added to conventional therapies have provided conflicting data. Recently, Breitkreutz et al. 23 reviewed the data from two prospective clinical trials that compared traditional VAD to a combination of thalidomide, doxorubicin and dexamethasone (TAD). Patients were mobilized with cyclophosphamide, doxorubicin, dexamethasone (CAD) followed by G-CSF. Within both the trials, patients receiving TAD collected significantly fewer CD34 þ cells compared with VAD. However, engraftment after stem cell transplantation showed no difference between the two groups. Nevertheless, the number of CD34 þ cells collected after these therapies was sufficient for tandem autologous transplantation in the majority of the patients. We had examined previously the effect of thalidomide administered as initial therapy on stem cell collection in a cohort of patients receiving stem cell transplant and found no effect on engraftment. Similar results were seen in a retrospective matched case-control analysis of 200 patients that compared Thal-Dex to VAD as initial therapy before autologous stem-cell transplantation for newly diagnosed multiple myeloma. 26 The groups which were matched for age, clinical stage and serum b2-microglobulin levels received four cycles of either regimen before proceeding to stem cell mobilization. Patients in each group received similar doses of cytoxan and G-CSF for mobilization at comparable intervals from the start of therapy. The median number of collected CD34 þ cells was 7.85 Â 10 6 /kg for patients receiving Thal-Dex and 10.5 Â 10 6 /kg for patients who received VAD, a difference that was not statistically significant. In both treatment groups, the median number of aphereses to collect adequate cell yields Total collection is the total number of CD34 þ cells collected over the total number of collections; # coll is the total number of aphereses procedures the patients underwent, daily avg is the average number of CD34 þ cells collected across the multiple aphereses procedures; day 1 is the CD34 þ collection on first day of apheresis, day 2 represents the total collection on the first 2 days and day 3 represents the total collection on the first 3 days. Abbreviations: Dex, dexamethasone; G-CSF, granulocyte-colony stimulating factor; Len-Dex, lenalidomide-dexamethasone; Thal-Dex, thalidomidedexamethasone; VAD, vincristine-adriamycin-dexamethasone.
Lenalidomide and stem cell mobilization in myeloma S Kumar et al was 2 and over 80% of patients collected enough cells for a tandem transplant. In a phase II study of Thal-Dex in 58 patients with newly diagnosed patients, collection of PBSCs was attempted after 3 months of treatment. The median yield was 8 Â 10 6 CD34 þ cells/kg, comparable to other studies and the authors concluded that there is no impact of thalidomide on stem cell collection. In the present study, we systematically included all patients in whom growth factor mobilization was initiated, again demonstrates no significant effect of thalidomide exposure on the ability to harvest PBSCs.
Lenalidomide, while it shares some of the mechanisms of thalidomide also differs significantly from thalidomide in terms of its hematological toxicity profile. While myelotoxicity was not a feature of thalidomide, cytopenias especially neutropenia is a prominent side-effect of lenalidomide with need for growth factor support in a substantial number of patients. In the phase II trial of lenalidomide and dexamethasone, where we treated 34 patients with newly diagnosed myeloma, 32% of patients had grade 1-2 neutropenia and 12% had grade 3-4 neutropenia. 15 Given this side-effect profile, there has been concern that þ yield across the multiple aphereses sessions (CD34 þ cells/kg, millions) and the age at collection (y-axis, years). lenalidomide may have an adverse impact on the ability to mobilize adequate numbers of stem cells, especially when tandem stem cell transplant approach is considered. We systematically studied all patients with multiple myeloma in whom stem cell mobilization was attempted at our institution over a 5-year period to capture all patients, who were treated with lenalidomide. To obtain a homogenous group of patients, we restricted the group to those patients having stem cells collected within the first 12 months of diagnosis. As has been demonstrated in the past, the stem cell yield is higher when patients are mobilized with chemotherapy and growth factors compared to either alone. 29, 30 Because of these differences, we elected to study these two groups separately. When compared to other therapies (Dex, VAD, Thal-Dex), initial treatment with lenalidomide was associated with reduced stem cell yield measured in terms of the total CD34 þ cell collection or the average CD34 þ cells per collection. These patients also required a greater number of aphereses to collect the targeted numbers of CD34 þ cells. This difference was marked in those receiving G-CSF alone for mobilization, while the small number of lenalidomide treated patients in the cyclophosphamide/G-CSF group precludes a definite conclusion regarding the effect of lenalidomide on stem cell harvest, though a similar trend was visible ( Figure 5 ).
Among the 48 patients receiving Len-Dex as initial therapy, only three patients completely failed to mobilize (6%), and an additional four patients (8%) failed to collect at least 4 million CD34 cells, the minimum stem cell harvest required for a tandem transplant. Importantly, the pretransplant therapy appeared to have no impact on the engraftment kinetics, once adequate numbers of stem cells are collected suggesting lack of any qualitative effect of lenalidomide on stem cells.
Exploration of our data points towards a possible effect of age and the duration of therapy on stem cell collection. The three Len-Dex patients who failed to mobilize cells were all older (over 67) and had received 7-11 months of therapy before attempted stem cell mobilization. While the number of patients included in this study precludes a definite conclusion, the results are suggestive enough for us to recommend early stem cell collection in patients being treated on lenalidomide based regimens. Previous studies have demonstrated reduced stem cell yields with other therapies as well when continued for more than 12 months from diagnosis before stem cell collection. 31 It is important to be aware of the potential for lenalidomide to reduce the stem cell yield as this combination becomes the standard regimen for initial treatment of myeloma. The potential deleterious effect is counterbalanced to a large extent by the anti-myeloma activity of lenalidomide combinations. The Total collection is the total number of CD34 þ cells collected over the total number of collections; # coll is the total number of aphereses procedures the patients underwent, daily avg is the average number of CD34 þ cells collected across the multiple aphereses procedures; day 1 is the CD34 þ collection on first day of apheresis, day 2 represents the total collection on the first 2 days and day 3 represents the total collection on the first 3 days. rapidity of response with lenalidomide containing regimens allow more rapid clinical improvement as well as disease control and hence potentially allow us to consider stem cell mobilization early on in the course of disease; earlier than the typical 4-6 months that has become the standard. It is important to note that none of the lenalidomide-treated patients, who had stem cells collected within 6 months of initiation of therapy failed to collect adequate numbers of cells for one transplant. The results of this study are not meant to guide the choice of initial therapy, since that needs to be made in relationship to the overall outcome of the patients. Newer regimens such as lenalidomide and low dose dexamethasone that are associated with lower early mortality may well be the initial therapy regimens of choice (Rajkumar SV, et al. Blood 2006; 108: 799, abstract). However, we need to be cognizant of the potential adverse effects of the drug on the ability to collect stem cells, especially in the era of tandem stem cell transplants with the requirement to collect additional stem cells. The results from this study should be confirmed in the larger prospective trials where parameters of stem cell yield should be routinely captured from those patients going to stem cell harvest. One limitation of this study is that it is retrospective and does not capture the proportion of patients who received induction therapy but failed to reach the point of stem cell mobilization either because of early mortality or significant morbidity. Recent results show that lenalidomide plus low dose Dex will result in more patients reaching the point of stem cell mobilization compared to other regimens because of significantly lower early mortality and morbidity compared to Dex, Thal/Dex (Rajkumar SV et al. Blood 2006; 108: 799, abstract). Chemotherapy-based mobilization strategies consistently give higher stem cell yields and could be considered in some of these patients with reduced CD34 yields related to initial therapy. 30 This is particularly relevant at a time when we are evaluating newer combinations of lenalidomide that incorporates other cytotoxic agents. Eventually, the impact may be minimal for the overall outcome of patients with newly diagnosed myeloma given the prolonged disease free survival seen with the newer agents and the possibility of deeper remission with the novel combinations. Improvements in the current therapy of myeloma could eventually replace high-dose therapy as a commonly utilized modality, which then would lessen any impact these drugs may have on the ability to collect stem cells. On the basis of longterm observations on the initial studies of lenalidomide, there does not appear to be any persistent long-term effect on myelopoiesis, even though longer term follow-up will be needed to make definitive conclusions. The exact mechanism of neutropenia related to lenalidomide remains incompletely understood at this time. Lenalidomide and stem cell mobilization in myeloma S Kumar et al
